Tous Actualités
Suivre
Abonner Deutsche Effecten- und Wechsel-Beteiligungsges. AG

Deutsche Effecten- und Wechsel-Beteiligungsges. AG

EANS-News: DEWB Investment Holding NOXXON Is Awarded Research and Development Grant for First-in-Human Clinical Trial with Spiegelmer® NOX-A12

Berlin, Germany, September 3, 2009 (euro adhoc) -

  Corporate news transmitted by euro adhoc. The issuer/originator is solely
  responsible for the content of this announcement.
Company Information/Investment holdings
NOXXON Pharma AG
(NOXXON), clinical-stage developer of L-RNA based scaffolds 
(Spiegelmers®) that bind their targets conceptually similar to 
antibodies, announced today that the company was awarded a research 
grant from Germany´s Federal Ministry of Education and Research 
(BMBF) under the ministry´s small and medium enterprise innovation 
initiative ("KMU-Innovativ"). The grant was presented to NOXXON 
following the completion of a peer reviewed selection process. Under 
the initiative NOXXON will receive 1.2 million Euro (1.7 million US$)
in funding for the impending phase I clinical development of its 
candidate Spiegelmer® NOX-A12. The company develops NOX-A12 for use 
in autologous hematopoietic stem cell transplantation in patients 
suffering from non-Hodgkin´s lymphoma or multiple myeloma.
NOXXON´s Chief Executive Officer Frank Morich commented: "In awarding
this competitive research grant to NOXXON, the BMBF acknowledges our 
tremendous progress in maturing Spiegelmer® compounds into 
therapeutic candidates for human use. The transition from 
pre-clinical studies to clinical trials is a critical junction in the
development of an innovative compound. We are grateful to the BMBF 
for providing grant support at this crucial stage."
Spiegelmers® (L-aptamers) are chemical entities based on synthetic 
mirror-image oligonucleotides. Due to their unique mirror image 
configuration Spiegelmers® are not metabolized and do not hybridize 
with native nucleic acids. Spiegelmers® also do not activate the 
innate immune response via Toll-like receptors and have shown an 
exceptionally favorable immunogenicity profile in pre-clinical 
testing. The phase I clinical development of NOX-A12 will follow 
closely behind that of NOXXON´s lead candidate NOX-E36, which entered
human testing in June of 2009.
About NOXXON Pharma AG: Berlin-based NOXXON Pharma AG is a 
clinical-stage biotechnology company focusing on the development of 
Spiegelmers® for the treatment of inflammatory diseases and 
hematological indications. In addition to its in-house programs 
NOXXON discovers and develops Spiegelmers® in collaboration with 
partners from the pharmaceutical industry, including Eli Lilly, 
Hoffmann La-Roche and Pfizer. Spiegelmers® (the German word "Spiegel"
means mirror) are chemical entities based on synthetic L-nucleic acid
scaffolds that bind their targets conceptually similar to monoclonal 
antibodies. They are highly selective for their pharmacological 
target and potent inhibitors of target function. The substance class 
exhibits exceptional metabolic stability and an outstanding 
immunogenicity profile - a new generation of improved therapeutics. 
NOXXON is an investment holding of the listed venture capital company
Deutsche Effecten- und Wechsel-Beteiligungsgesellschaft AG (DEWB), 
headquartered in Jena.
Website: http://www.noxxon.com
General contact:
Emmanuelle Delabre
NOXXON Pharma AG
Max-Dohrn-Strasse 8-10
10589 Berlin, Germany
Phone: + 49-30-726247-100
FAX: + 49-30-726247-225
Email:  edelabre@noxxon.com
end of announcement                               euro adhoc

Further inquiry note:

Marco Scheidler
Tel.: +49 (0) 3641 573-3600
E-Mail: marco.scheidler@dewb-vc.com

Branche: Financial & Business Services
ISIN: DE0008041005
WKN: 804100
Index: CDAX, Classic All Share, Prime All Share
Börsen: Frankfurt / regulated dealing/prime standard
Berlin / free trade
Stuttgart / free trade
München / free trade

Plus de actualités: Deutsche Effecten- und Wechsel-Beteiligungsges. AG
Plus de actualités: Deutsche Effecten- und Wechsel-Beteiligungsges. AG
  • 29.07.2009 – 11:50

    EANS-News: Sloning BioTechnology and Henkel to Co-Operate in Enzyme Development

    Corporate news transmitted by euro adhoc. The issuer/originator is solely responsible for the content of this announcement. companies/DEWB investment holding Puchheim/Düsseldorf, 29 June 2009 (euro adhoc) - Multinational consumer chemicals company Henkel will use Sloning BioTechnology´s proprietary protein engineering platform in their Laundry and Home ...

  • 06.05.2009 – 12:05

    EANS-News: ACiG Technology to distribute KSW Microtec´s RFID Thinlam®

    Corporate news transmitted by euro adhoc. The issuer/originator is solely responsible for the content of this announcement. investments/DEWB AG/Portfolio companies Mainz/Dresden, Germany (euro adhoc) - KSW Microtec AG, one of the world´s leading suppliers of RFID components and inlays for secure cards, documents and other form factors, announced today that ...